EXBLIFEP Drug Patent Profile

Which patents cover Exblifep, and when can generic versions of Exblifep launch?

Exblifep is a drug marketed by Orchid Pharma and is included in one NDA. There are two patents protecting this drug.

This drug has twenty-five patent family members in eighteen countries.

The generic ingredient in EXBLIFEP is cefepime hydrochloride; enmetazobactam. There are twenty drug master file entries for this compound. Additional details are available on the cefepime hydrochloride; enmetazobactam profile page.

DrugPatentWatch^® Generic Entry Outlook for Exblifep

Exblifep will be eligible for patent challenges on February 22, 2028. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be February 22, 2034. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for EXBLIFEP

International Patents:	25
US Patents:	2
Applicants:	1
NDAs:	1
What excipients (inactive ingredients) are in EXBLIFEP?	EXBLIFEP excipients list
DailyMed Link:	EXBLIFEP at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for EXBLIFEP

Constraining patent/regulatory exclusivity:

GENERATING ANTIBIOTIC INCENTIVES NOW

NDA:

216165

Dosage:

POWDER;INTRAVENOUS

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

US Patents and Regulatory Information for EXBLIFEP

EXBLIFEP is protected by two US patents and two FDA Regulatory Exclusivities.

This potential generic entry date is based on GENERATING ANTIBIOTIC INCENTIVES NOW.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Orchid Pharma	EXBLIFEP	cefepime hydrochloride; enmetazobactam	POWDER;INTRAVENOUS	216165-001	Feb 22, 2024		DISCN	Yes	No			Y	Y
Orchid Pharma	EXBLIFEP	cefepime hydrochloride; enmetazobactam	POWDER;INTRAVENOUS	216165-001	Feb 22, 2024		DISCN	Yes	No
Orchid Pharma	EXBLIFEP	cefepime hydrochloride; enmetazobactam	POWDER;INTRAVENOUS	216165-001	Feb 22, 2024		DISCN	Yes	No
Orchid Pharma	EXBLIFEP	cefepime hydrochloride; enmetazobactam	POWDER;INTRAVENOUS	216165-001	Feb 22, 2024		DISCN	Yes	No

International Patents for EXBLIFEP

See the table below for patents covering EXBLIFEP around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	2014345507
Canada	2929199
Chile	2016001097
China	105873935
Eurasian Patent Organization	031348

Last updated: July 13, 2026

EXBLIFEP market dynamics and financial trajectory: pricing, uptake, payer coverage, and pathway to revenue

No complete, verifiable public record is available here to determine the marketed drug identity, FDA/label status, launch date, revenue trajectory, payer mix, or IP/regulatory context for “EXBLIFEP.” Without confirmation of the active ingredient, dosage form, and regulatory status, a financially actionable market-dynamics assessment would risk misidentifying the product.

What is Exblifep (EXBLIFEP) and what does its label cover?

A market and financial trajectory depends on the exact marketed product entity (active ingredient, strength, dosage form, route), FDA approval date, and indication set. These label attributes are not available in the provided context, so coverage, utilization drivers, and competitive substitution cannot be tied to the correct drug.

What are the active ingredient and dosage form behind EXBLIFEP?

Market dynamics and pricing benchmarks require the correct molecule and presentation. “EXBLIFEP” is not sufficient to anchor to an FDA-approved drug entry, which prevents mapping to:

• FDA label indications
• REMS requirements (if any)
• specialty pharmacy vs retail dynamics
• dosing cadence and treatment duration

What FDA approval pathway does EXBLIFEP use (NDA, BLA, 505(b)(2))?

Pathway affects launch speed, copay structures, and payer contracting. No verifiable pathway information is available for EXBLIFEP here.

How fast did EXBLIFEP launch and ramp sales versus peers?

A ramp-speed view requires at minimum: launch quarter, net sales by year, and prescribing or unit volume trends. None of these are available in the provided context.

What launch timeline indicators determine ramp velocity?

Key indicators normally include:

• time to formulary placement
• time to meaningful covered lives
• time to specialty pharmacy stocking
• mean sales script or prescriptions per provider

These cannot be computed without confirmed product identity and payer data.

What payer coverage and reimbursement patterns shape EXBLIFEP’s revenue?

Revenue trajectory in branded specialty drugs is driven by coverage breadth and patient access constraints.

Is EXBLIFEP covered by commercial formularies, Medicare Part D, and Medicaid?

Coverage requires identifying the drug in payer formularies and CMS-related datasets; no product mapping is possible from “EXBLIFEP” alone here.

What utilization management exists for EXBLIFEP (prior auth, step therapy, quantity limits)?

Utilization management materially changes net-to-gross and patient access. No label or payer policy detail is available for EXBLIFEP in the provided context.

How strong is the competitive position of EXBLIFEP in its therapeutic category?

Competitive dynamics require knowing:

• mechanism of action and clinical differentiation
• first-line versus second-line placement
• comparison set of branded and generic/therapeutic alternatives

Those drivers depend on confirmed drug identity and indication set, which are not available here.

What pricing strategy and discounting drive EXBLIFEP’s net sales?

Financial trajectory depends on ASP behavior, rebates, and patient cost-sharing design.

What are EXBLIFEP’s WAC, net price, and rebate profile proxies?

Without a verifiable NDC-to-ingredient mapping, no WAC/ASP trajectory, rebate benchmark, or discount rate can be tied to EXBLIFEP.

How do copay and patient assistance programs affect demand?

Copay structures influence script conversion and persistence. No verifiable copay or manufacturer assistance details are available.

How do market dynamics change around formulary wins, label expansions, and competitor entries?

To model revenue inflection points, you need:

• label expansion dates
• major payer negotiations
• competitor approvals and launch dates

No verified timeline exists for EXBLIFEP here.

When do label expansions typically impact volume for similar drugs?

General patterns exist, but applying them to EXBLIFEP without confirmed indication changes would be speculative.

What is EXBLIFEP’s revenue exposure: product lifecycle, channel mix, and cost structure?

A financial trajectory view must include:

• net sales and margins
• channel mix (hospital vs retail vs specialty)
• manufacturing scale-up economics

No confirmed financial disclosure, manufacturer identity, or product entity is available.

What IP and regulatory milestones could affect EXBLIFEP’s future market share?

IP risk determines expected competitive encroachment and cashflow durability.

What patents protect EXBLIFEP (composition, formulation, method-of-use)?

No patent estate mapping is possible without confirmed active ingredient and FDA/Orange Book record.

When does EXBLIFEP lose exclusivity, and what generic entry risks exist?

Exclusivity and Paragraph IV risk require Orange Book and litigation mappings. These cannot be produced for EXBLIFEP from the provided context.

What litigation or settlements could shape EXBLIFEP’s commercial runway?

IP disputes and settlements typically change launch calendars, market access timing, and net sales.

No litigation docket linkages are available for EXBLIFEP here.

How does EXBLIFEP compare with closest alternatives on clinical and commercial metrics?

A like-for-like comparison requires confirmed:

• indication
• mechanism class
• trial endpoints or real-world outcomes
• pricing and payer access

No product identity is available.

---

Key Takeaways

• No complete, verifiable market or financial trajectory analysis can be produced for “EXBLIFEP” without confirmed drug identity (active ingredient, FDA approval status, dosage form, and label).
• Market dynamics inputs needed for an actionable assessment (net sales trend, payer coverage, pricing/discounting, formulary access timing, IP/regulatory calendar) are not available in the provided context.

FAQs

1. What is the FDA status of EXBLIFEP and which label indications drive revenue?
2. What is EXBLIFEP’s expected exclusivity timeline and generic entry risk window?
3. What payer coverage metrics predict EXBLIFEP net-to-gross performance in the first 24 months?
4. Which branded or biosimilar alternatives most constrain EXBLIFEP’s market share by line of therapy?
5. What patent litigation and settlement history affects the timing of competitive launches versus EXBLIFEP?

References

(No sources cited because the provided context does not include enough information to identify EXBLIFEP’s FDA product record, IP estate, or financial disclosures.)

DrugChatter Q&A for EXBLIFEP

How does Exblifep treat UTIs?